Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.

Medicare and Medicaid spent more than $18 billion over four years on accelerated approval drugs with late post-market trials that are meant to confirm the drugs work, according to the HHS Inspector General, which released its findings the same day the Senate passed FDA user fee legislation from which accelerated approval reforms were stripped.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.